[Federal Register Volume 69, Number 107 (Thursday, June 3, 2004)]
[Notices]
[Pages 31412-31413]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 04-12462]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration


Manufacturer of Controlled Substances; Notice of Application

    Pursuant to section 1301.33(a) of Title 21 of the Code of Federal 
Regulations (CFR), this is notice that on March 29, 2004, Abbott 
Laboratories, DBA Knoll Pharmaceutical Company, 30 North Jefferson 
Road, Whippany, New Jersey 07981, made application by renewal to the 
Drug Enforcement Administration (DEA) for registration as a bulk 
manufacturer of the basic classes of controlled substances listed 
below:

------------------------------------------------------------------------
                    Drug                               Schedule
------------------------------------------------------------------------
Dihydromorphine (9145).....................  I
Hydromorphine (9150).......................  II
------------------------------------------------------------------------

    The firm plans to manufacture bulk product and finished dosage 
units for distribution to its customers.
    Any other such applicant and any person who is presently registered 
with DEA to manufacture such substance may file comments or objections 
to the issuance of the proposed registration.
    Any such comments or objections may be addressed, in quintuplicate, 
to the Deputy Assistant Administrator, Office of Diversion Control, 
Drug Enforcement Administration, United States Department of Justice, 
Washington, DC 20537, Attention: Federal Register Representative, 
Office

[[Page 31413]]

of Chief Counsel (CCD) and must be filed no later than August 2, 2004.

William J. Walker,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
[FR Doc. 04-12462 Filed 6-2-04; 8:45 am]
BILLING CODE 4410-09-M